Carbapenems
Phase 2Small molecule
Carbapenems is one of 5 small molecule programs targeting Escherichia coli Infections. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Escherichia Coli Infections
#DrugCompanyPhaseTrials
1Levaquin
WWim Janssens
Approved
Fluzone
SanofiPhase 3
Cefotan
BB. Braun Medical Inc.
Phase 2
Beta Lactam Antibiotics
OOregon Health and Science University
Phase 2
Carbapenems
OOregon Health and Science University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carbapenems. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details